NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that they have completed Phase I of their In-Life dose escalation study. The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. There were two phases with the first phase of the study being completed in September of 2019.
Phase I In-Life Dose Escalation Study
- Searching for the maximum feasible volume.
- Initiated at 0.5 ml/kg, and then increased to 1.0 mg/kg, 1.5 mg/kg, and 2.0 mg/ kg once daily approximately every 18-24 hours.
- Found no visible lesions on any of trial patients.
"Management is pleased that our BioLexa Platform continues to demonstrate an impressive safety profile during its testing phase," said, Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics. "We believe this therapeutic candidate has the potential to provide significant benefits to people afflicted by Atopic Dermatitis. Going forward, we are focused on expanding our clinical efforts into later stage trials."
This stage of the toxicity study was designed to determine dose-limiting adverse events and to define the maximum tolerated dose of the BioLexa Platform. The BioLexa Platform is a proprietary, patented therapeutic designed for the treatment of atopic dermatitis.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
SOURCE Hoth Therapeutics, Inc.